Patients with immunoglobin A nephropathy who reached complete remission of proteinuria with sparsentan had greater eGFR ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...

Data from Boehringer Ingelheim’s Phase II apecotrep study was published in The Lancet and presented at the 2025 ASN’s Kidney Week ...

Proteinuria is a condition characterised by the presence of excess protein, mainly albumin, in the urine. Generally, the kidneys filter waste products and excess fluids from the blood and excrete them ...

Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...

Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

Proteinuria is common in the adult population and its clinical significance can vary widely. A clear diagnostic process is needed to identify the cause of the findings and guide the treatment ...

Proteinuria (protein in urine) is common with complement 3 glomeropathy and is a strong predictor of disease progression and end-stage kidney failure.

Before a drug is marketed in the US, it must be shown to be safe and effective for its intended use. The clearest evidence of a drug's effectiveness comes from studies establishing its effects on ...

Understanding eGFR and uPCR is vital for managing IgA nephropathy to predict kidney health, guide treatment, and work ...

German family-owned pharma major Boehringer Ingelheim today announced results from a Phase II trial evaluating apecotrep (BI 764198) as a novel, targeted, non-immunosuppressive therapy in people with ...